Article Text

Download PDFPDF
436 Cost effectiveness of a board certified surgical oncologist risk reduction surgery implementation for cancer predisposition women in the Brazilian national health system (sus): an interim analysis
  1. Vandré Cabral Gomes Carneiro1,
  2. Nathalia Moreira Ramalho2,
  3. Manoel Rodrigues De Andrade Neto3,
  4. Rodrigo Arruda4,
  5. Jurema telles De Oliveira Lima Sales5,
  6. Gabrielly Leite Mattos6,
  7. Roberto Borges Bezerra2,
  8. Candice Lima Santos2,
  9. Thales Paulo Batista7 and
  10. Luiz Odorico Monteiro De Andrade8
  1. 1IMIP/HCP/SES-PE HBL/D’OR, Recife, Brazil
  2. 2IMIP/D’OR, Recife, Brazil
  3. 3IMIP/HBL/D’OR, Recife, Brazil
  4. 4HCP/IMIP/D´OR, Recife, Brazil
  5. 5IMIP/SES-PE/D’OR, Recife, Brazil
  6. 6FPS, Recife, Brazil
  7. 7UFPE/RHP, Recife, Brazil
  8. 8FIOCRUZ, Fortaleza, Brazil

Abstract

Introduction/Background The identification of women with a hereditary predisposition to breast and ovarian cancer from the segregation of the presence of a familial known pathogenic variant in BRCA1 is a strategy that allows the recognition of ovarian cancer’s high-risk women, which may provide risk-reducing bilateral salpingo-oophorectomy (RRBSO), reducing the risk of cancer of the peritoneum, fallopian tubes and ovaries from around 71 to 96%. Board certified surgeons are more likely to adhere to best practice techniques when performing RRBSO. The objective of this pilot study is to evaluate the cost-effectiveness of a board certified surgical oncologist Risk Reduction Surgery implementation for cancer predisposition women in the Brazilian National Health System (SUS).

Methodology It will be calculated the treatment’s cost of Pernambuco’s Hereditary Cancer Program‘s women diagnosed with ovarian cancer and a germline pathogenic variant in BRCA1; the cost of the genetic test for women in the family; the possible cost in the treatment of malignant neoplasms diagnosed in these women, calculating the penetrance of ovarian cancer in this specific population, comparing the cost with the genetic tests and the board certified surgical oncologist Risk Reduction Surgeries.

Results An interim analysis reveals that the media of the treatment’s cost of women diagnosed with ovarian cancer and a germline pathogenic variant in BRCA1 was R$ 52286,7; The cost with the genetic tests and the board certified surgical oncologist Risk Reduction Surgery were R$ 285 and R$ 4566,27, respectively. These risk reduction strategy could avoid the cost of R$ 33460,9 = Є$ 6357,6, for every prevented ovarian cancer.

Conclusion The primary anaysis should be considered a cost-effectiveness of board certified surgical oncologist Risk Reduction Surgery implementation for pathogenic variants BRCA1 women in Pernambuco’s families with hereditary predisposition to breast and ovarian cancer in the Brazilian National Health System (SUS).

Disclosures The authors has no conflict of interest.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.